Drug Type Nanobody, Tetraspecific antibody |
Synonyms SM 2275, SM2275 |
Action agonists, antagonists, inhibitors, + [1] |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | IND Approval | United States | 05 Apr 2025 | |
Solid tumor | Preclinical | China | 15 May 2024 |